Cellectar Biosciences, Inc.
CLRB
$2.37
-$0.05-1.87%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 23.21% | 15.09% | 51.12% | 62.38% | 45.11% |
| Total Depreciation and Amortization | -89.04% | -81.73% | -26.74% | -20.57% | -6.25% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 129.86% | 106.45% | 201.19% | -300.32% | -147.89% |
| Change in Net Operating Assets | 208.50% | 136.26% | -81.19% | -4,718.76% | 10.24% |
| Cash from Operations | 43.68% | 57.39% | 51.42% | 35.83% | 23.44% |
| Capital Expenditure | 84.83% | 88.74% | 94.34% | 80.21% | 93.24% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 84.83% | 88.74% | 94.34% | 80.21% | 93.24% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 114.19% | -25.79% | -78.78% | -90.43% | -70.34% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 114.19% | -25.79% | -78.78% | -87.00% | -70.34% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 254.80% | 78.73% | -173.54% | -242.10% | -171.58% |